secwatch.observer — SEC 8-K summary
======================================

Issuer:     Compass Therapeutics, Inc. (CMPX)
CIK:        0001738021
Form:       8-K
Filed at:   2022-08-19T23:59:59+00:00
Accession:  0001171843-22-005763
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Compass Therapeutics director Stephen Squinto resigns from board effective Aug 31
--------------------------------------------------------------------------------

- Stephen Squinto, Ph.D., notified Compass of his resignation from the Board and all committees, effective August 31, 2022.
- Resignation not due to any disagreement with the Company on operations, policies, or practices.
- Dr. Squinto had been a Board member since 2015, representing an early investor; he is leaving to pursue other professional endeavors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1738021/000117184322005763/0001171843-22-005763-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1738021/000117184322005763/f8k_081922.htm
  HTML page:      https://secwatch.observer/filing/0001171843-22-005763

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer